TriangleSacituzumab tirumotecan (NCT07438626)
Sacituzumab tirumotecan trial for Phase II (NCT07438626). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic SMARCB1-deficient renal medullary carcinoma after progression on earlier treatment. The SMARCB1-negative medullary-phenotype variant without sickle hemoglobin disease is also eligible.
The idea: test sacituzumab tirumotecan infusions. This antibody-drug conjugate binds TROP2 on tumor cells and delivers a cell-killing payload. Researchers assess tumor response, disease control and safety. Prior TROP2-targeted or topoisomerase-one-payload antibody-drug conjugates exclude participation. Kidney removal is not required. Companion laboratory studies require consent.
This phase 2 study plans 20 patients. Pavlos Msaouel leads MD Anderson's recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.